Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 1/20 | 0.53 |
| ▸ | ANPEP | P15144 | 1/20 | 0.53 |
| ▸ | CTRB1 | P17538 | 3/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | TACR1 | P25103 | 3/20 | 0.52 |
| ▸ | CTSL | P07711 | 2/20 | 0.51 |
| ▸ | CTSB | P07858 | 1/20 | 0.51 |
| ▸ | CTSS | P25774 | 1/20 | 0.51 |
| ▸ | CTSK | P43235 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL30168523 | 1.00 | MME (0.53) | MMEANPEPCTRB1POLBALDH1A1 | |
| SCHEMBL25000465 | 0.94 | POLB (0.58) | MMEANPEPCTRB1POLBALDH1A1 | |
| SCHEMBL9252529 | 0.89 | TSHR (0.59) | MMEANPEPCTRB1POLBALDH1A1 | |
| SCHEMBL30538862 | 0.86 | LTA4H (0.61) | MMEANPEPPOLB | |
| SCHEMBL19316083 | 0.86 | MMP1 (0.55) | MMEANPEPPOLBALDH1A1THRB | |
| SCHEMBL2367498 | 0.86 | CTSS (0.46) | MMEANPEPCTRB1CTSLCTSB | |
| Trifluoroacetic Acid SCHEMBL10443782 | 0.84 | CTSK (0.54) | CTSLCTSBCTSSCTSK | |
| SCHEMBL10330406 | 0.84 | MME (0.56) | MMEANPEPPOLBALDH1A1THRB | |
| SCHEMBL10953335 | 0.83 | ALDH1A1 (0.58) | MMECTRB1POLBALDH1A1THRB | |
| SCHEMBL12293600 | 0.83 | ALDH1A1 (0.51) | MMEANPEPCTRB1POLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240350649-A1 | TREATMENT AND DIAGNOSIS OF IMMUNE DISORDERS RELATING TO ABERRANT IMMUNE CELLS | OCTAGON THERAPEUTICS, INC. | 2024-10-24 | — | — | US | disclosed |
| WO-2023014360-A1 | TREATMENT AND DIAGNOSIS OF IMMUNE DISORDERS RELATING TO ABERRANT IMMUNE CELLS | OCTAGON THERAPEUTICS, INC. (US) | 2023-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240350649-A1 | TREATMENT AND DIAGNOSIS OF IMMUNE DISORDERS RELATING TO ABERRANT IMMUNE CELLS | CD74, SERPINA6, CD2BP2 | MME 3726/4885ANPEP 1976/4885CTRB1 2640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.